Mega Genomics Past Earnings Performance
Past criteria checks 2/6
Mega Genomics's earnings have been declining at an average annual rate of -39.2%, while the Healthcare industry saw earnings growing at 4.8% annually. Revenues have been declining at an average rate of 18.2% per year. Mega Genomics's return on equity is 4.7%, and it has net margins of 19.9%.
Key information
-39.2%
Earnings growth rate
n/a
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | -18.2% |
| Return on equity | 4.7% |
| Net Margin | 19.9% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Mega Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 151 | 30 | 75 | 0 |
| 30 Sep 23 | 149 | 15 | 89 | 0 |
| 30 Jun 23 | 147 | 0 | 103 | 0 |
| 31 Mar 23 | 146 | -9 | 103 | 0 |
| 31 Dec 22 | 146 | -18 | 104 | 0 |
| 30 Sep 22 | 192 | 22 | 84 | 0 |
| 30 Jun 22 | 238 | 62 | 65 | 0 |
| 31 Mar 22 | 238 | 70 | 58 | 0 |
| 31 Dec 21 | 237 | 79 | 52 | 0 |
| 31 Dec 20 | 203 | 79 | 35 | 0 |
| 31 Dec 19 | 124 | 30 | 27 | 0 |
Quality Earnings: 6667 has high quality earnings.
Growing Profit Margin: 6667 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6667's earnings have declined by 39.2% per year over the past 5 years.
Accelerating Growth: 6667 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6667 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (13.4%).
Return on Equity
High ROE: 6667's Return on Equity (4.7%) is considered low.